Diabetes

Medical Disclaimer: This information is intended for educational purposes only and should not be considered medical advice. It is crucial for clinicians to exercise independent medical judgment and consult official guidelines and primary literature for the most current and accurate information. Patient care decisions must always be individualized based on the patient's specific condition, comorbidities, and preferences.

Overview

• Definition: Diabetes mellitus (DM) is a chronic metabolic disorder characterized by elevated blood glucose levels (hyperglycemia) resulting from defects in insulin secretion, insulin action, or both. Chronic hyperglycemia is associated with long-term damage, dysfunction, and failure of various organs, especially the eyes, kidneys, nerves, heart, and blood vessels.
• Epidemiology:
  • Globally, an estimated 537 million adults aged 20-79 years were living with diabetes in 2021, and this number is projected to rise to 643 million by 2030 and 783 million by 2045 (IDF Diabetes Atlas, 10th ed.).
  • In the United States, approximately 37.3 million people (11.3% of the population) have diabetes, with 8.5 million undiagnosed. Additionally, 96 million adults (38.0%) have prediabetes (CDC, 2022).
  • Type 2 Diabetes Mellitus (T2DM) accounts for 90-95% of all diagnosed cases. Type 1 Diabetes Mellitus (T1DM) accounts for 5-10%.
  • Prevalence is increasing worldwide, driven by factors like rising rates of obesity and sedentary lifestyles. Disparities exist across racial/ethnic groups, with higher prevalence among certain minority populations.
• Classification:
  • Type 1 Diabetes Mellitus (T1DM): Characterized by autoimmune β-cell destruction, usually leading to absolute insulin deficiency.
    • Immune-mediated: Most common form, involves autoimmune destruction of pancreatic β-cells.
    • Idiopathic: Less common, without evidence of autoimmunity.
  • Type 2 Diabetes Mellitus (T2DM): Characterized by progressive loss of β-cell insulin secretion, often on the background of insulin resistance.
  • Gestational Diabetes Mellitus (GDM): Diabetes diagnosed in the second or third trimester of pregnancy that was not clearly overt diabetes prior to gestation.
  • Other Specific Types of Diabetes:
    • Monogenic Diabetes Syndromes: Neonatal diabetes or Maturity-Onset Diabetes of the Young (MODY).
    • Diseases of the Exocrine Pancreas: Cystic fibrosis-related diabetes, pancreatitis.
    • Drug- or Chemical-Induced Diabetes: Glucocorticoids, antiretroviral agents, organ transplant medications.
    • Endocrinopathies: Cushing's syndrome, acromegaly, pheochromocytoma.

Pathophysiology

• Mechanism:
  • Type 1 Diabetes: Primarily an autoimmune disease where the body's immune system mistakenly attacks and destroys the insulin-producing β-cells in the pancreatic islets. This leads to a severe or absolute deficiency of insulin, requiring exogenous insulin for survival. Genetic predisposition and environmental triggers are thought to play roles.
  • Type 2 Diabetes: Characterized by a combination of insulin resistance (where target cells like muscle, fat, and liver do not respond effectively to insulin) and progressive β-cell dysfunction (leading to insufficient insulin secretion to overcome the resistance). Initially, the pancreas compensates by increasing insulin production, but eventually, β-cells fail to meet the demand, leading to hyperglycemia. Impaired incretin effect and increased hepatic glucose production also contribute.
  • Gestational Diabetes: Placental hormones (e.g., human placental lactogen, estrogen, progesterone, cortisol) induce insulin resistance during pregnancy to ensure adequate nutrient supply to the fetus. If the mother's pancreas cannot produce enough insulin to compensate for this increased resistance, GDM develops.
• Risk Factors:
  • Type 1 Diabetes: Family history of T1DM, specific HLA genotypes (e.g., DR3/DR4), other autoimmune diseases (e.g., Hashimoto's thyroiditis, celiac disease). Environmental triggers (viruses, early diet) are suspected but not fully established.
  • Type 2 Diabetes:
    • Non-modifiable: Family history of T2DM, age ≥ 45 years, certain ethnicities (African American, Hispanic/Latino, American Indian/Alaska Native, Asian American, Pacific Islander).
    • Modifiable: Overweight or obesity (BMI ≥ 25 kg/m², or ≥ 23 kg/m² for Asian Americans), physical inactivity, unhealthy diet, hypertension (≥ 140/90 mmHg or on medication), dyslipidemia (HDL-C < 35 mg/dL and/or triglycerides > 250 mg/dL), history of GDM, polycystic ovary syndrome (PCOS), history of cardiovascular disease.
  • Gestational Diabetes: History of GDM in previous pregnancy, previous delivery of a large infant (>9 lbs), obesity, family history of T2DM, certain ethnicities, advanced maternal age.
• Protective Factors:
  • Type 1 Diabetes: Currently, no established primary prevention for T1DM. Research is ongoing regarding immunomodulatory therapies for at-risk individuals.
  • Type 2 Diabetes: Regular physical activity (≥150 min/week of moderate-intensity aerobic activity), healthy diet (e.g., Mediterranean diet, DASH diet), weight loss (5-7% of body weight for individuals with prediabetes), smoking cessation.
  • Gestational Diabetes: Pre-pregnancy healthy weight, healthy diet, and regular physical activity may reduce risk.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Polyuria: Frequent urination, especially at night (nocturia), due to osmotic diuresis from glycosuria.
  • Polydipsia: Increased thirst, a compensatory mechanism for fluid loss.
  • Polyphagia: Increased hunger, as cells cannot effectively utilize glucose for energy.
  • Unexplained Weight Loss: Particularly common in T1DM, due to fluid loss and caloric deficit despite increased appetite.
• Early Signs:
  • Fatigue/Lethargy
  • Blurred vision (due to osmotic changes in the lens)
  • Recurrent infections (e.g., skin infections, candidiasis, UTIs)
  • Slow-healing sores or wounds
  • Tingling or numbness in hands/feet (early neuropathy)
• Advanced Signs:
  • Symptoms of macrovascular complications: Chest pain (angina), leg pain with walking (claudication), transient ischemic attack (TIA) or stroke symptoms.
  • Symptoms of microvascular complications: Decreased vision/blindness (retinopathy), swelling of legs, foam in urine (nephropathy), severe neuropathic pain, foot ulcers, gangrene.
  • Signs of acute complications:
    • Diabetic Ketoacidosis (DKA): Nausea, vomiting, abdominal pain, Kussmaul respirations (deep, rapid breathing), fruity breath odor (acetone), altered mental status. More common in T1DM.
    • Hyperosmolar Hyperglycemic State (HHS): Severe dehydration, altered mental status, seizures, profound hyperglycemia without significant ketosis. More common in T2DM, especially in elderly.
• Atypical Presentations:
  • Often asymptomatic, especially in early T2DM, diagnosed incidentally on routine blood tests.
  • Presenting with a complication: Myocardial infarction, stroke, new onset kidney disease, chronic non-healing wound, recurrent infections.
  • In children/adolescents, T2DM can present without classic polyuria/polydipsia, often detected on screening due to obesity or family history.

Physical Examination

• Inspection:
  • Skin: Acanthosis nigricans (darkening and thickening of skin in skin folds, especially neck and axilla, indicative of insulin resistance), skin tags, chronic non-healing ulcers (especially on feet), evidence of fungal infections (e.g., candidiasis, tinea pedis), lipodystrophy (at insulin injection sites), xanthelasma, necrobiosis lipoidica diabeticorum.
  • Eyes: Direct ophthalmoscopy may reveal signs of diabetic retinopathy (microaneurysms, hemorrhages, exudates, neovascularization). Eyelid xanthomas.
  • Feet: Deformities (Charcot foot), calluses, fissures, signs of infection, signs of peripheral artery disease (PAD) like thin, shiny skin, hair loss.
  • Oral cavity: Periodontal disease, oral candidiasis.
• Palpation:
  • Peripheral Pulses: Assess dorsalis pedis, posterior tibial, popliteal, and femoral pulses. Diminished or absent pulses suggest PAD.
  • Temperature and sensation: Assess for symmetry and warmth/coolness, especially in extremities. Test light touch, pinprick, vibration, and proprioception.
• Special Tests:
  • Neuropathy Screening:
    • 10-g Monofilament Test: To assess pressure sensation; loss of protective sensation is a key risk factor for foot ulcers.
    • Vibration Perception Threshold: Using a 128-Hz tuning fork.
    • Ankle Reflexes: Diminished or absent Achilles reflex (may indicate peripheral neuropathy).
  • Ankle-Brachial Index (ABI): If PAD is suspected (symptoms, abnormal foot pulses). ABI < 0.9 suggests PAD.
  • Fundoscopy: To screen for diabetic retinopathy. Often requires pupil dilation for thorough examination.
  • Blood Pressure Measurement: Orthostatic hypotension testing in suspected autonomic neuropathy.

Diagnostic Approach

History Taking

• Key Questions:
  • Symptoms: Presence and duration of polyuria, polydipsia, polyphagia, weight loss, blurred vision, numbness/tingling, fatigue, recurrent infections, slow-healing wounds.
  • Risk Factors: Family history of diabetes, personal history of GDM or PCOS, history of cardiovascular disease, hypertension, dyslipidemia.
  • Lifestyle: Diet (typical food intake, sugary drinks), physical activity level, smoking status, alcohol consumption.
  • Medications: Current medications, especially those that can affect glucose levels (e.g., corticosteroids, atypical antipsychotics).
  • Social History: Access to healthy food, ability to exercise, social support.
  • Complications: Any symptoms suggesting microvascular (visual changes, kidney issues, neuropathic pain, foot problems) or macrovascular complications (chest pain, claudication, stroke symptoms).
  • For T1DM: Any recent viral infections, rapid onset of symptoms, DKA history.
• Red Flags:
  • Rapid onset of polyuria, polydipsia, weight loss, and fatigue (especially in children/young adults) - suggestive of T1DM and potential DKA.
  • Nausea, vomiting, abdominal pain, Kussmaul breathing, fruity odor on breath, altered mental status – signs of DKA.
  • Profound dehydration, severe hyperglycemia (often >600 mg/dL), altered mental status – signs of HHS.
  • Sudden blurred vision, severe peripheral neuropathy, non-healing foot ulcers.

Laboratory Tests

• First-Line: Diagnosis of diabetes (non-pregnant adults) requires one of the following criteria, confirmed by repeat testing (unless clear hyperglycemia with acute metabolic decompensation or unequivocal symptoms):
  • Fasting Plasma Glucose (FPG): ≥ 126 mg/dL (7.0 mmol/L)
    • Fasting defined as no caloric intake for at least 8 hours.
  • 2-hour Plasma Glucose (PG) during Oral Glucose Tolerance Test (OGTT): ≥ 200 mg/dL (11.1 mmol/L)
    • Using a glucose load containing 75 g anhydrous glucose dissolved in water.
  • Hemoglobin A1c (HbA1c): ≥ 6.5% (48 mmol/mol)
    • Performed in a laboratory using a method certified by the NGSP and standardized to the DCCT assay.
  • Random Plasma Glucose (RPG): ≥ 200 mg/dL (11.1 mmol/L) in patients with classic symptoms of hyperglycemia (polyuria, polydipsia, unexplained weight loss) or hyperglycemic crisis.
  • Prediabetes Definition:
    • FPG 100-125 mg/dL (5.6-6.9 mmol/L)
    • 2-h PG during OGTT 140-199 mg/dL (7.8-11.0 mmol/L)
    • HbA1c 5.7–6.4% (39–47 mmol/mol)
• Confirmatory:
  • If initial screening test is positive but without symptoms or acute crisis, a second test (preferably the same one) should be performed on a subsequent day to confirm the diagnosis. If results are discordant (e.g., FPG elevated, HbA1c normal), the test whose result is above the diagnostic cut point should be repeated.
  • For T1DM Diagnosis/Differentiation:
    • C-peptide: Low or undetectable C-peptide levels indicate severe insulin deficiency (characteristic of T1DM).
    • Autoantibodies: Islet cell autoantibodies (ICA), glutamic acid decarboxylase autoantibodies (GADA or anti-GAD65), insulin autoantibodies (IAA), tyrosine phosphatase IA-2 autoantibodies (IA-2A), zinc transporter 8 autoantibodies (ZnT8A). Presence supports a diagnosis of autoimmune T1DM.
• Monitoring:
  • Glycemic Control:
    • HbA1c: Routinely measured at least twice a year in patients meeting treatment goals and who have stable glycemic control; quarterly in patients whose therapy has changed or who are not meeting glycemic goals.
    • Self-Monitoring of Blood Glucose (SMBG): Frequency depends on treatment regimen (e.g., multiple times daily for insulin users, less often for oral agents). Continuous Glucose Monitoring (CGM) provides more comprehensive data.
  • Complications Screening:
    • Lipid Panel: Annually or more frequently if abnormal. Target LDL-C <100 mg/dL (or <70 mg/dL for high-risk CVD).
    • Kidney Function:
      • Serum Creatinine and eGFR: Annually.
      • Urine Albumin-to-Creatinine Ratio (UACR): Annually (first morning void preferred). Normal <30 mg/g. Microalbuminuria 30-299 mg/g. Macroalbuminuria ≥300 mg/g.
    • Thyroid-stimulating hormone (TSH): Annually for T1DM, especially at diagnosis, due to increased risk of autoimmune thyroid disease.
    • Other: Comprehensive dilated eye exam annually (or every 2 years if no retinopathy and well-controlled), comprehensive foot exam annually.

Imaging

• Recommended: Imaging is generally not used for the diagnosis of diabetes itself but is crucial for assessing and monitoring complications.
  • Retinal Photography/Optical Coherence Tomography (OCT): For assessment and monitoring of diabetic retinopathy and macular edema.
  • Renal Ultrasound: If nephropathy is progressive or obstructive uropathy is suspected.
  • Cardiac Imaging (Echocardiogram, Stress Test, CT Angiography): For evaluation of cardiovascular disease (e.g., coronary artery disease, cardiomyopathy) based on symptoms or risk assessment.
  • Peripheral Artery Disease (PAD) Imaging (e.g., Doppler Ultrasound, Angiography): If PAD is suspected (abnormal ABI, claudication, non-healing wounds).
  • Foot X-rays/MRI: To assess for osteomyelitis, Charcot arthropathy, or other foot pathologies in patients with ulcers or suspected infections.
• Advanced:
  • PET-CT: In specific cases to assess for large vessel inflammation or occult infections.
  • Functional Brain Imaging: In research settings for cognitive decline related to diabetes.

Management

Acute Management

• Immediate:
  • Diabetic Ketoacidosis (DKA) / Hyperosmolar Hyperglycemic State (HHS):
    • Fluid Resuscitation: Initiate rapidly with isotonic saline (0.9% NaCl). Typical initial rate 1-1.5 L/hr, then adjusted based on hydration status and electrolytes. Switch to 0.45% NaCl when serum Na+ is normal/high. Add Dextrose (D5W) when blood glucose reaches ~200 mg/dL (DKA) or ~250-300 mg/dL (HHS) to prevent hypoglycemia and allow continued insulin infusion.
    • Insulin Infusion: Start continuous IV regular insulin infusion (e.g., 0.1 U/kg/hr) after initial fluid bolus. Maintain glucose reduction rate of 50-75 mg/dL/hr.
    • Electrolyte Repletion:
      • Potassium: Crucial to monitor and replete, as insulin shifts K+ intracellularly. If K+ <3.3 mEq/L, delay insulin until K+ is corrected. If K+ 3.3-5.2 mEq/L, add 20-40 mEq K+ to each liter of IV fluid.
      • Bicarbonate: Generally not recommended unless pH <6.9 in DKA.
      • Phosphate: Only if severe hypophosphatemia or cardiac dysfunction.
  • Severe Hypoglycemia (Glucose <54 mg/dL / 3.0 mmol/L, or symptomatic and unable to self-treat):
    • Conscious Patient: Oral glucose (15-20g rapid-acting carbohydrate: e.g., 4 oz juice, 3-4 glucose tablets). Recheck glucose in 15 mins. Repeat if still low.
    • Unconscious/Unable to Swallow:
      • IV Dextrose: 25g (50 mL of D50W) IV push. Recheck glucose in 10-15 mins.
      • Glucagon: 1 mg SC/IM (adults). May cause nausea/vomiting.
• Stabilization:
  • Continuous monitoring of blood glucose, electrolytes, fluid status, vital signs.
  • Address precipitating factors (infection, medication non-adherence).
  • Transition from IV insulin to subcutaneous insulin when metabolic goals are met (e.g., anion gap closure, resolution of acidosis, patient eating). Overlap IV and SC insulin for 1-2 hours to prevent rebound hyperglycemia.
• Emergency:
  • Management of life-threatening complications (e.g., cerebral edema in DKA, severe hypokalemia, acute cardiovascular events).
  • Consultation with critical care specialists as needed.

Chronic Management

• Pharmacological: Individualize treatment based on patient characteristics, comorbidities, glucose levels, and risk of hypoglycemia.
  • First-line for T2DM: Metformin (unless contraindicated, e.g., eGFR <30 mL/min/1.73m²). Initial dose 500 mg once daily, titrate up to 1000-2000 mg/day (or 850 mg twice daily). Reduces hepatic glucose production.
  • Agents with Cardiovascular (CV) and/or Renal Benefits:
    • GLP-1 Receptor Agonists (GLP-1 RAs): Liraglutide, semaglutide, dulaglutide. Injectable (oral semaglutide available). Promote glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, promote satiety. Proven CV benefit (reduced MACE). Renoprotective effects. Common side effects: GI (nausea, vomiting).
    • Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Empagliflozin, canagliflozin, dapagliflozin, ertugliflozin. Oral. Increase urinary glucose excretion. Proven CV benefit (reduced MACE and heart failure hospitalization). Proven renoprotective effects. Common side effects: Genitourinary infections, dehydration.
  • Other Oral Agents (typically added after metformin or if metformin is contraindicated/not tolerated):
    • DPP-4 Inhibitors: Sitagliptin, saxagliptin, linagliptin, alogliptin. Oral. Enhance incretin effect, increasing glucose-dependent insulin secretion. Weight neutral, low hypoglycemia risk.
    • Sulfonylureas (SUs): Glipizide, glimepiride, glyburide. Oral. Stimulate insulin secretion from β-cells. Risk of hypoglycemia and weight gain. Generally used with caution in elderly.
    • Thiazolidinediones (TZDs): Pioglitazone, rosiglitazone. Oral. Improve insulin sensitivity in peripheral tissues. Risk of weight gain, edema, heart failure exacerbation, bone fractures. Pioglitazone may have some CV benefit.
  • Insulin Therapy (essential for T1DM, often needed for T2DM progression):
    • Basal Insulin: Long-acting (e.g., glargine, detemir, degludec) or intermediate-acting (NPH). Provides background insulin coverage.
    • Bolus/Prandial Insulin: Rapid-acting (e.g., lispro, aspart, glulisine) or short-acting (regular). Covers carbohydrate intake and corrects hyperglycemia.
    • Insulin Regimens: Basal-bolus, multiple daily injections (MDI), continuous subcutaneous insulin infusion (CSII or insulin pump).
    • Dosage: Highly individualized. Initial dosing often 0.1-0.2 U/kg/day for T2DM (basal), 0.4-1.0 U/kg/day for T1DM. Titrated based on glucose monitoring.
• Non-pharmacological: Foundation of diabetes management.
  • Medical Nutrition Therapy (MNT): Individualized meal planning with a registered dietitian. Focus on balanced macronutrients, consistent carbohydrate intake, portion control, reduced saturated/trans fats and refined carbohydrates.
  • Physical Activity: At least 150 minutes/week of moderate-intensity aerobic physical activity (e.g., brisk walking) spread over at least 3 days/week, with no more than 2 consecutive days without activity. Incorporate resistance training 2-3 times/week.
  • Weight Management: For overweight/obese individuals, sustained weight loss (e.g., 5-10%) significantly improves glycemic control and reduces CV risk. Bariatric surgery may be considered for BMI ≥40 kg/m² (or ≥35 kg/m² with comorbidities).
  • Diabetes Self-Management Education and Support (DSMES): Essential for empowering patients to manage their condition, monitor glucose, adjust medication, prevent complications, and cope with the psychological burden.
  • Smoking Cessation: Crucial for reducing cardiovascular and microvascular complication risk.
  • Alcohol Moderation: Can affect blood glucose levels and interact with medications.
• Monitoring:
  • Glycemic Control:
    • HbA1c: Target often <7.0% (53 mmol/mol) for most adults, but individualized based on age, comorbidities, risk of hypoglycemia, and diabetes duration. Less stringent for elderly/frail (<8.0%).
    • SMBG/CGM: Regular review of glucose logs to identify patterns and guide therapy adjustments.
  • Blood Pressure: Target <130/80 mmHg for most adults with diabetes. ACE inhibitors or ARBs are often first-line, especially if albuminuria is present.
  • Lipid Management: Statin therapy for most adults with diabetes. Intensity depends on age and ASCVD risk. Target LDL-C <70 mg/dL (1.8 mmol/L) for very high risk.
  • Kidney Function: Annual UACR and eGFR. Initiate SGLT2i/GLP-1 RA for CKD.
  • Foot Examination: Comprehensive annual exam including inspection, pulse palpation, and 10-g monofilament test.
  • Eye Examination: Annual dilated comprehensive eye exam by an ophthalmologist or optometrist.
  • Vaccinations: Annual influenza vaccine, pneumococcal vaccines (PCV15/20), hepatitis B vaccine (for unvaccinated adults <60 years old).

Treatment Algorithms

• First-Line (T2DM):
  1. Lifestyle Modifications: MNT, physical activity, weight management.
  2. Metformin: Initiated at diagnosis unless contraindicated.
  3. Consider ASCVD, CKD, or Heart Failure:
     • If ASCVD or indicators of high ASCVD risk (age ≥55 with CAD, cerebrovascular disease, or PAD, or >2 risk factors), CKD (eGFR <60 ml/min/1.73m² or UACR >30 mg/g), or Heart Failure (especially HFrEF) are present, add an SGLT2 inhibitor or GLP-1 receptor agonist with proven CV/renal benefit, regardless of HbA1c and in addition to metformin.
• Second-Line (T2DM - If not at target HbA1c after 3 months, or no compelling indication for SGLT2i/GLP-1 RA):
  1. Choose agent based on patient factors:
     • Weight loss desired: GLP-1 RA, SGLT2i.
     • Minimize hypoglycemia: GLP-1 RA, SGLT2i, DPP-4i, TZD.
     • Cost considerations: Sulfonylurea (generics inexpensive).
     • Comorbidities: Refer to First-Line (ASCVD/CKD/HF).
  2. Add second agent: Options include SGLT2i, GLP-1 RA, DPP-4i, SU, TZD. If not already on it, consider an agent with CV/renal benefit.
  3. Intensification: If not at target with two oral agents, consider adding a third oral agent, GLP-1 RA, or basal insulin.
• Refractory Cases:
  • Multiple daily injections (MDI) of insulin or insulin pump therapy: If oral agents/GLP-1 RAs are insufficient to reach glycemic targets. This is typically the standard for T1DM management from diagnosis.
  • Combination injectable therapy: Basal insulin + GLP-1 RA (fixed-ratio combinations available).
  • Intensified insulin regimens: Basal-bolus (basal insulin plus prandial insulin with meals).
  • Advanced therapies for obesity: Bariatric surgery for eligible patients (BMI ≥40 kg/m² or ≥35 kg/m² with comorbidities) can lead to significant and sustained weight loss and diabetes remission in many cases.
  • Pancreas or islet transplantation: Considered for select patients with T1DM, typically those with severe hypoglycemia, kidney failure, or failed kidney transplant.

Complications

• Common:
  • Hypoglycemia: Blood glucose <70 mg/dL (3.9 mmol/L). Can be mild, moderate, or severe. Symptoms: sweating, tremor, hunger, palpitations, anxiety, confusion, dizziness, blurred vision, seizures, loss of consciousness.
  • Hyperglycemia: Above target range. Acute symptoms: polyuria, polydipsia, fatigue.
  • Diabetic Foot Ulcers: Open sores on the feet due to neuropathy and/or peripheral artery disease, highly prone to infection.
  • Infections: Increased susceptibility to skin infections, UTIs, candidiasis (oral, vaginal), pneumonia, and surgical site infections.
  • Hypertension: Very common comorbidity.
  • Dyslipidemia: Atherogenic lipid profile (high triglycerides, low HDL-C, small dense LDL-C).
• Serious:
  • Diabetic Ketoacidosis (DKA): Life-threatening acute complication of T1DM (and some T2DM), characterized by hyperglycemia, metabolic acidosis, and ketosis.
  • Hyperosmolar Hyperglycemic State (HHS): Life-threatening acute complication of T2DM, characterized by extreme hyperglycemia, hyperosmolarity, and severe dehydration without significant ketoacidosis.
  • Severe Hypoglycemia: Requires assistance from another person, can lead to seizures, coma, or death.
  • Cardiovascular Disease (CVD): Leading cause of morbidity and mortality in diabetes. Includes coronary artery disease (angina, MI), stroke, peripheral artery disease (PAD).
  • End-Stage Renal Disease (ESRD): Diabetes is the leading cause of ESRD, requiring dialysis or kidney transplant.
  • Blindness: Diabetic retinopathy is a leading cause of preventable blindness in working-age adults.
  • Amputations: Due to diabetic foot ulcers, infection, and PAD.
• Long-term:
  • Macrovascular Complications: Affect large blood vessels.
    • Coronary Artery Disease (CAD): Angina, myocardial infarction.
    • Cerebrovascular Disease: Stroke, transient ischemic attack (TIA).
    • Peripheral Artery Disease (PAD): Claudication, non-healing ulcers, critical limb ischemia, increased risk of amputation.
  • Microvascular Complications: Affect small blood vessels.
    • Diabetic Retinopathy: Damage to retinal blood vessels, leading to vision impairment or blindness.
    • Diabetic Nephropathy: Damage to kidney's filtering units, leading to proteinuria, progressive decline in kidney function, and ESRD.
    • Diabetic Neuropathy: Nerve damage.
      • Peripheral Neuropathy: Sensory (numbness, tingling, pain) and motor (muscle weakness, foot deformities).
      • Autonomic Neuropathy: Affects organ function (gastroparesis, erectile dysfunction, orthostatic hypotension, silent ischemia, bladder dysfunction).

Prognosis

• Factors:
  • Glycemic Control: Achieving and maintaining individualized HbA1c targets significantly reduces the risk and progression of microvascular and macrovascular complications.
  • Duration of Diabetes: Longer duration generally correlates with increased risk of complications.
  • Presence of Complications at Diagnosis: Patients already presenting with complications have a worse prognosis.
  • Comorbidities: Coexisting hypertension, dyslipidemia, obesity, and established cardiovascular disease worsen prognosis.
  • Lifestyle Factors: Adherence to healthy diet, regular exercise, smoking cessation, and weight management positively impacts outcomes.
  • Access to Care: Regular monitoring, patient education, and timely intervention by a multidisciplinary team improve prognosis.
  • Genetic Factors: May influence susceptibility to complications.
• Survival: Diabetes significantly reduces life expectancy, primarily due to increased risk of cardiovascular disease (which accounts for ~60-80% of deaths in people with diabetes). Individuals with T1DM have an average reduced life expectancy of 10-15 years, and T2DM 5-10 years, compared to non-diabetic individuals. Early diagnosis and intensive management can mitigate this.
• Quality of Life: Diabetes can significantly impair quality of life due to the burden of daily self-management, the development of chronic complications (e.g., neuropathy leading to pain/amputations, retinopathy leading to vision loss, kidney failure requiring dialysis), and associated psychological distress (e.g., diabetes distress, depression, anxiety). Effective management, education, and psychological support are crucial for maintaining QoL.

Prevention

• Primary: Aims to prevent the onset of diabetes, particularly T2DM, in individuals at high risk (e.g., those with prediabetes).
  • Intensive Lifestyle Interventions: Demonstrated to be highly effective.
    • Weight loss: Modest, sustained weight loss (e.g., 5-7% of initial body weight).
    • Physical Activity: Regular moderate-intensity physical activity (e.g., ≥150 minutes/week).
    • Dietary Changes: Reduced intake of saturated/trans fats, refined carbohydrates, and sugary drinks; increased intake of whole grains, fiber, fruits, and vegetables.
  • Pharmacological Prevention:
    • Metformin: Can be considered for T2DM prevention in high-risk individuals (e.g., those with prediabetes, BMI ≥35 kg/m², age <60 years, and women with history of GDM), especially if lifestyle interventions are insufficient.
• Secondary: Aims for early detection and intervention to prevent or delay the progression of diabetes or its complications.
  • Screening:
    • T2DM: Universal screening for all adults ≥35 years of age. Repeat every 1-3 years if results are normal. Earlier and more frequent screening for individuals with risk factors (e.g., obesity, family history, GDM history).
    • GDM: Screen all pregnant women not previously diagnosed with diabetes at 24-28 weeks gestation (using a 1-step 75g OGTT or 2-step approach).
  • Intensive Glycemic Control: For newly diagnosed diabetes, achieving and maintaining individualized glycemic targets can reduce the risk of microvascular and macrovascular complications.
  • Aggressive Management of Comorbidity Risk Factors: Blood pressure control, lipid management, and antiplatelet therapy (if indicated).
• Tertiary: Aims to prevent or slow the progression of existing diabetes complications and improve quality of life.
  • Comprehensive Diabetes Management: Optimize glycemic control, blood pressure, and lipid levels.
  • Regular Screening for Complications: Annual dilated eye exams, annual comprehensive foot exams, annual UACR/eGFR.
  • Early Intervention for Complications: Prompt treatment of retinopathy (laser, anti-VEGF), nephropathy (ACEi/ARB, SGLT2i), neuropathy (pain management, foot care), and macrovascular disease (statins, antiplatelets, revascularization).
  • Patient Education and Empowerment: Ongoing DSMES to foster self-management skills and adherence.

Special Populations

• Pediatric:
  • T1DM: Most common type in children. Management focuses on insulin therapy (MDI or pump), carbohydrate counting, preventing DKA, supporting normal growth and development, and addressing psychosocial impact. Strict glycemic control can be challenging due to unpredictable eating and activity patterns.
  • T2DM: Incidence increasing, strongly linked to obesity and family history. Management includes lifestyle modification, metformin. Insulin or GLP-1 RAs may be used if glycemic goals not met or if severe hyperglycemia.
  • Screening: T2DM screening for overweight/obese youth with additional risk factors (family history, minority race/ethnicity, signs of insulin resistance) beginning at age 10 or at onset of puberty.
• Geriatric:
  • Increased prevalence of T2DM. Often have multiple comorbidities, polypharmacy, functional limitations, and increased risk of hypoglycemia unawareness.
  • Glycemic Targets: Less stringent HbA1c targets (e.g., <8.0% for frail patients with multiple comorbidities) to reduce hypoglycemia risk.
  • Medication Selection: Avoid sulfonylureas if possible. Prioritize agents with low hypoglycemia risk (e.g., DPP-4i, GLP-1 RA, SGLT2i) and consider renal function.
  • Complication Screening: Prioritize screening for complications that significantly impact function and quality of life (e.g., visual impairment, foot problems, cognitive decline).
  • Frailty Assessment: Incorporate assessment of frailty, cognitive function, and functional status into management plans.
• Pregnancy:
  • Gestational Diabetes Mellitus (GDM): Screening at 24-28 weeks. Management primarily with MNT and physical activity. If targets not met, insulin is the preferred pharmacological agent. Metformin may be used. Strict glycemic control (FPG <95 mg/dL, 1-h post-meal <140 mg/dL, 2-h post-meal <120 mg/dL) to prevent macrosomia and adverse fetal/maternal outcomes.
  • Pre-existing Diabetes in Pregnancy: Intensive management from pre-conception. Strict glycemic targets (HbA1c <6.5% pre-conception and in pregnancy if achievable without significant hypoglycemia). Increased risk of congenital anomalies and other adverse outcomes if not well-controlled. All diabetes medications except insulin are generally discontinued or carefully reviewed.
  • Postpartum: Women with GDM should be screened for persistent diabetes at 4-12 weeks postpartum (75g OGTT). Lifetime risk of T2DM is significantly increased for women with GDM.
• Comorbidities:
  • Cardiovascular Disease (CVD): Diabetes is a major risk factor. Prioritize SGLT2i or GLP-1 RA with proven CV benefit. Aggressive BP and lipid management. Antiplatelet therapy (aspirin) for secondary prevention.
  • Chronic Kidney Disease (CKD): Diabetes is the leading cause. Prioritize SGLT2i (with specific eGFR thresholds) and GLP-1 RA for renoprotection. ACEi/ARB for blood pressure and albuminuria management. Dose adjustments for many medications required based on eGFR.
  • Heart Failure (HF): SGLT2i have proven benefits in reducing HF hospitalization and CV death, regardless of presence of diabetes (particularly for HFrEF). Avoid TZDs.
  • Obesity: Central to T2DM pathogenesis. Emphasize weight management, including lifestyle, pharmacological agents (GLP-1 RAs lead to significant weight loss), and bariatric surgery.

Clinical Pearls

• Diagnostic:
  • Don't rely solely on HbA1c for diagnosis in acute settings: HbA1c may not reflect acute changes in glucose. Use plasma glucose tests (FPG, RPG) for diagnosis in acutely ill patients.
  • Consider T1DM in adults: Latent Autoimmune Diabetes in Adults (LADA) is common; older age at diagnosis does not rule out T1DM. Look for rapid onset, weight loss, or positive autoantibodies.
  • Prediabetes is not benign: It carries increased risk for macrovascular complications and progression to T2DM. Initiate lifestyle interventions aggressively.
• Treatment:
  • Individualize glycemic targets: "One size fits all" HbA1c target is inappropriate. Consider age, duration of diabetes, comorbidities, and risk of hypoglycemia.
  • Prioritize CV and renal benefits: For patients with established ASCVD, CKD, or heart failure, SGLT2 inhibitors and GLP-1 receptor agonists should be used regardless of HbA1c, due to their organ-protective effects.
  • Metformin is king: Unless contraindicated or not tolerated, metformin remains the foundational drug for T2DM due to its efficacy, safety, cost-effectiveness, and potential CV benefits.
  • Educate for hypoglycemia: Teach patients and their families how to recognize and treat hypoglycemia. Glucagon rescue pens/nasal powder should be prescribed for patients at risk of severe hypoglycemia.
• Pitfalls:
  • Clinical Inertia: Failure to timely intensify therapy when patients are not at glycemic targets, leading to prolonged hyperglycemia and increased complication risk.
  • Over-treatment in the Elderly/Frail: Leading to dangerous hypoglycemia, falls, and reduced quality of life.
  • Missing Non-Glucose Related Targets: Neglecting blood pressure and lipid management, which are equally if not more important for preventing macrovascular complications.
  • Ignoring Psychosocial Aspects: Diabetes distress, depression, and anxiety are common and can severely impact adherence and outcomes. Screen for and address these issues.
  • Neglecting Foot Care: Failure to perform regular comprehensive foot exams and educate patients on daily foot inspection can lead to preventable amputations.

Recent Updates

• Guidelines:
  • ADA Standards of Medical Care in Diabetes (annual update): Continually refines recommendations based on new evidence. Latest version (2024) reinforces the use of SGLT2 inhibitors and GLP-1 RAs for patients with or at high risk for ASCVD, HF, or CKD.
  • EASD-ADA Consensus Report: Provides detailed guidance on the management of hyperglycemia in T2DM.
• Evidence:
  • Expanding Indications for SGLT2i: Evidence for heart failure benefit extends to patients without diabetes (e.g., EMPEROR-Preserved, DELIVER trials). Their role in CKD management is now robustly established (e.g., DAPA-CKD, EMPA-KIDNEY trials).
  • Dual GLP-1/GIP Agonists (e.g., tirzepatide): Demonstrate superior HbA1c reduction and weight loss compared to GLP-1 RAs alone. Evidence for CV outcome trials is emerging (SURMOUNT, SURPASS trials).
  • Oral Semaglutide: Provides an oral option for GLP-1 RA therapy, improving patient convenience and adherence.
• Controversies:
  • Optimal Glycemic Targets: Ongoing debate regarding the precise HbA1c target for certain populations, especially very elderly, frail, or those with long-standing diabetes and established complications, where the risks of intensive therapy may outweigh benefits.
  • Role of Bariatric/Metabolic Surgery: While highly effective for weight loss and T2DM remission, discussions continue regarding optimal patient selection (e.g., lower BMI thresholds) and long-term nutritional implications.
  • Screening for T1DM: Research explores the feasibility and benefits of population-level screening for T1DM autoantibodies in at-risk children to identify individuals early and potentially intervene before symptomatic onset.

Key References

• Guidelines:
  • American Diabetes Association (ADA) Standards of Medical Care in Diabetes: Published annually in Diabetes Care. The definitive guideline for diabetes management in the US.
  • European Association for the Study of Diabetes (EASD) Guidelines: Often developed in collaboration with the ADA (e.g., ADA/EASD Consensus Report on the Management of Hyperglycemia in Type 2 Diabetes).
  • National Institute for Health and Care Excellence (NICE) Guidelines (UK): Comprehensive and evidence-based clinical guidelines.
• Studies:
  • Diabetes Control and Complications Trial (DCCT) & Epidemiology of Diabetes Interventions and Complications (EDIC): Landmark studies establishing the benefit of intensive glycemic control in T1DM for preventing microvascular complications.
  • UK Prospective Diabetes Study (UKPDS): Found that intensive glycemic control and blood pressure control significantly reduced microvascular and macrovascular complications in T2DM.
  • ACCORD, ADVANCE, VADT Trials: Investigated intensive glycemic control in T2DM, highlighting risks in certain populations.
  • LEADER, SUSTAIN-6, CANVAS, EMPA-REG OUTCOME, DECLARE-TIMI 58, DAPA-HF, EMPEROR-Reduced, DELIVER, EMPA-KIDNEY, DAPA-CKD: Pivotal cardiovascular and renal outcome trials for GLP-1 RAs and SGLT2 inhibitors, demonstrating their benefits beyond glucose lowering.
• Reviews:
  • UpToDate: Comprehensive, evidence-based clinical reviews.
  • Endocrinology, Diabetes, and Metabolism Clinics of North America: Special issues focused on various aspects of diabetes.
  • Lancet Diabetes & Endocrinology: Leading peer-reviewed journal publishing original research and reviews.